Marissa Shapiro
-
Discovery and communication key to biochemistry Ph.D. Kaitlyn Browning
Class of 2024: See how Ph.D. candidate Kaitlyn Browning wants to fight miscommunication and misinformation around science. Read MoreFeb. 16, 2024
-
Vanderbilt nanodrug may be a paradigm shift for cancer
A multidisciplinary research team at Vanderbilt University and Vanderbilt University Medical Center has discovered a new way to kill a tumor by disrupting its acidic “microenvironment” without harming normal tissue. The target of this unorthodox approach is hydroxyapatite (HAP), a naturally occurring mineral that is a major component of bone and teeth, but which also is produced by some tumors. Read MoreFeb. 13, 2024
-
Lab-to-Table Conversation: ‘Picturing Progress: Representation in Scientific Art’ is Feb. 20
Join the next Lab-to-Table conversation, “Picturing Progress: Representation in Scientific Art” on Feb. 20 at 11:00 a.m. Read MoreFeb. 7, 2024
-
Combining unique methods, Kuriyan lab discovers new protein functions; explores physical space of proteins
Combining deep mutagenesis and cryo-EM reveals new conformational state of a protein responsible for high-speed DNA replication. The research builds on growing theories of molecular evolution. Read MoreFeb. 6, 2024
-
‘Molecular Muse’ exhibit features Artist-in-Residence program’s science-inspired art
The “Molecular Muse” exhibit is a sampling of pieces from the Vanderbilt Institute for Infection, Immunology and Inflammation Artist-in-Residence (VI4-AiR) program. The program was recently awarded a fourth year of funding from the Burroughs Wellcome Fund. Read MoreJan. 23, 2024
-
Vanderbilt chemist Ben Brown awarded $2.375M to develop nonaddictive painkillers with AI
Avenir Award funding from the National Institute on Drug Abuse recognizes research that represents “the future of addiction science.” Brown’s research is creating an AI-experiment feedback loop that will help optimize painkilling drugs to be less addictive. Read MoreJan. 19, 2024
-
First successful clinical trial of VU319 brings Alzheimer’s treatment one step closer
Phase I clinical trial of a drug was successfully completed at the Warren Center for Neuroscience Drug Discovery, with promise to treat Alzheimer’s and other neurodegenerative diseases. The compound, named VU319, is the first Vanderbilt end-to-end drug discovery effort related to memory loss, starting from the earliest basic science research through human clinical trials. Read MoreJan. 19, 2024
-
Lab-to-Table Conversation: Beyond Addiction: Therapeutic Developments and Societal Impact, on Jan. 24
Join the next Lab-to-Table conversation, “Beyond Addiction: Therapeutic Developments and Societal Impact” on Jan. 24 at 11:30 a.m. CT. Read MoreJan. 11, 2024
-
Innovation Ignition Fund launches a pilot program to support early-stage therapeutic projects with translational viability
The School of Medicine Basic Sciences and the Office of the Vice Provost for Research and Innovation launch the Innovation Ignition Fund. This pilot program offers up to $500,000 in funding and drug development mentorship from Vanderbilt scientists with expertise in translational research. Read MoreJan. 8, 2024
-
Anti-aging researcher Monica Driscoll, Rutgers University, to present Apex Lecture on January 8
Anti-aging researcher and National Academy of Sciences member Monica Driscoll (Rutgers University) to deliver the Vanderbilt Basic Sciences Apex Lecture. Read MoreDec. 14, 2023